Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q2JS
|
|||
| Former ID |
DIB002275
|
|||
| Drug Name |
SB-282241
|
|||
| Synonyms |
CCR2B antagonists, GlaxoSmithKline; SB-380732; MCP-1 antagonists, GlaxoSmithKline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Terminated | [1], [2] | |
| Company |
SmithKline Beecham Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H31Cl2N3O2
|
|||
| Canonical SMILES |
C1CN(CCC1C2=CNC3=C2C=C(C=C3)O)CCCCCNC(=O)C=CC4=CC(=C(C=C4)Cl)Cl
|
|||
| InChI |
1S/C27H31Cl2N3O2/c28-24-7-4-19(16-25(24)29)5-9-27(34)30-12-2-1-3-13-32-14-10-20(11-15-32)23-18-31-26-8-6-21(33)17-22(23)26/h4-9,16-18,20,31,33H,1-3,10-15H2,(H,30,34)/b9-5+
|
|||
| InChIKey |
QBRLVMQBZIFWTB-WEVVVXLNSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 2 (CCR2) | Target Info | Antagonist | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Reactome | Beta defensins | |||
| Chemokine receptors bind chemokines | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Defensins | ||||
| Spinal Cord Injury | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 782). | |||
| REF 2 | CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem. 2003 Sep 11;46(19):4070-86. | |||
| REF 3 | Patent EP2727944 A1. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.